Abstract
The recent bestowal of the Nobel Prize 2019 in Physiology or Medicine to Gregg L. Semenza, Sir Peter J. Ratcliffe, and William G. Kaelin Jr. celebrates a series of remarkable discoveries that span from the physiological research question on how oxygen deficiency (hypoxia) induces the red blood cell forming hormone erythropoietin (Epo) to the first clinical application of a novel family of Epo-inducing drugs to treat patients suffering from renal anemia. This review looks back at the most important findings made by the three Nobel laureates, highlights current research trends, and sheds an eye on future perspectives of hypoxia research, including emerging and potential clinical applications.
Similar content being viewed by others
References
Adams DF, Watkins MS, Durette L, Laliberte J, Goulet F, Debien E, Frazier KS, Mellal N, Chen L, Shi W, Thomas R, Hu E (2019) Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor. Toxicol Pathol:192623319880445. https://doi.org/10.1177/0192623319880445
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162:1401–1408. https://doi.org/10.1001/archinte.162.12.1401
Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23:1631–1634. https://doi.org/10.1681/asn.2011111078
Batie M, Frost J, Frost M, Wilson JW, Schofield P, Rocha S (2019) Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science 363:1222–1226. https://doi.org/10.1126/science.aau5870
Beck J, Henschel C, Chou J, Lin A, Del Balzo U (2017) Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats. Int J Toxicol 36:427–439. https://doi.org/10.1177/1091581817737232
Berchner-Pfannschmidt U, Tug S, Trinidad B, Oehme F, Yamac H, Wotzlaw C, Flamme I, Fandrey J (2008) Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide. J Biol Chem 283:31745–31753. https://doi.org/10.1074/jbc.M804390200
Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schödel J, Reisenbuechler A, Klaus S, Arend M, Flippin L, Willam C, Wiesener MS, Yard B, Warnecke C, Eckardt KU (2009) Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci USA 106:21276–21281
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21:2151–2156
Bishop T, Ratcliffe PJ (2015) HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res 117:65–79. https://doi.org/10.1161/circresaha.117.305109
Blumberg A, Keller H, Marti HR (1973) Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur J Clin Invest 3:93–97. https://doi.org/10.1111/j.1365-2362.1973.tb00334.x
Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337–1340
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485–490
Cavadas MA, Mesnieres M, Crifo B, Manresa MC, Selfridge AC, Keogh CE, Fabian Z, Scholz CC, Nolan KA, Rocha LM, Tambuwala MM, Brown S, Wdowicz A, Corbett D, Murphy KJ, Godson C, Cummins EP, Taylor CT, Cheong A (2016) REST is a hypoxia-responsive transcriptional repressor. Sci Rep 6:31355. https://doi.org/10.1038/srep31355
Chakraborty AA, Laukka T, Myllykoski M, Ringel AE, Booker MA, Tolstorukov MY, Meng YJ, Meier SR, Jennings RB, Creech AL, Herbert ZT, McBrayer SK, Olenchock BA, Jaffe JD, Haigis MC, Beroukhim R, Signoretti S, Koivunen P, Kaelin WG Jr (2019) Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science 363:1217–1222. https://doi.org/10.1126/science.aaw1026
Chan MC, Ilott NE, Schodel J, Sims D, Tumber A, Lippl K, Mole DR, Pugh CW, Ratcliffe PJ, Ponting CP, Schofield CJ (2016) Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) prolyl and asparaginyl hydroxylases. J Biol Chem 291:20661–20673. https://doi.org/10.1074/jbc.M116.749291
Chandra M, Clemons GK, McVicar MI (1988) Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113:1015–1021. https://doi.org/10.1016/s0022-3476(88)80573-0
Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C et al (2019) Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381:1011–1022. https://doi.org/10.1056/NEJMoa1901713
Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L et al (2019) Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381:1001–1010. https://doi.org/10.1056/NEJMoa1813599
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C et al (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539:112–117. https://doi.org/10.1038/nature19796
Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA, Wallace EM, Kaelin WG (2016) On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature 539:107–111. https://doi.org/10.1038/nature19795
Choudhry H, Schödel J, Oikonomopoulos S, Camps C, Grampp S, Harris AL, Ratcliffe PJ, Ragoussis J, Mole DR (2014) Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2. EMBO Rep 15:70–76
Chowdhury R, Leung IK, Tian YM, Abboud MI, Ge W, Domene C, Cantrelle FX, Landrieu I, Hardy AP, Pugh CW, Ratcliffe PJ, Claridge TD, Schofield CJ (2016) Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases. Nat Commun 7:12673. https://doi.org/10.1038/ncomms12673
Cockman ME, Lippl K, Tian YM, Pegg HB, Figg WDJ, Abboud MI, Heilig R, Fischer R, Myllyharju J, Schofield CJ, Ratcliffe PJ (2019) Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. eLife 8. https://doi.org/10.7554/eLife.46490
Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733–25741
Cockman ME, Webb JD, Kramer HB, Kessler BM, Ratcliffe PJ (2009) Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics 8:535–546
Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouysségur J, Taylor CT (2006) Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc Natl Acad Sci USA 103:18154–18159
Cummins EP, Comerford KM, Scholz C, Bruning U, Taylor CT (2007) Hypoxic regulation of NF-κB signaling. Methods Enzymol 435:479–492. https://doi.org/10.1016/s0076-6879(07)35025-8
Davis CK, Jain SA, Bae ON, Majid A, Rajanikant GK (2018) Hypoxia mimetic agents for ischemic stroke. Front Cell Dev Biol 6:175. https://doi.org/10.3389/fcell.2018.00175
Dhillon S (2019) Roxadustat: first global approval. Drugs 79:563–572. https://doi.org/10.1007/s40265-019-01077-1
Ebert BL, Bunn HF (1998) Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 18:4089–4096
Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J Biol Chem 281:15215–15226
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54
Feldman DE, Chauhan V, Koong AC (2005) The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 3:597–605. https://doi.org/10.1158/1541-7786.mcr-05-0221
Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ (1994) Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci USA 91:6496–6500
Goldberg MA, Dunning SP, Bunn HF (1988) Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242:1412–1415
Goldberg MA, Glass GA, Cunningham JM, Bunn HF (1987) The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 84:7972–7976
Grampp S, Platt JL, Lauer V, Salama R, Kranz F, Neumann VK, Wach S, Stohr C, Hartmann A, Eckardt KU, Ratcliffe PJ, Mole DR, Schodel J (2016) Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. Nat Commun 7:13183. https://doi.org/10.1038/ncomms13183
Grampp S, Schmid V, Salama R, Lauer V, Kranz F, Platt JL, Smythies J, Choudhry H, Goppelt-Struebe M, Ratcliffe PJ, Mole DR, Schödel J (2017) Multiple renal cancer susceptibility polymorphisms modulate the HIF pathway. PLoS Genet 13:e1006872. https://doi.org/10.1371/journal.pgen.1006872
Haase VH (2017) HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodialysis international International Symposium on Home Hemodialysis 21(Suppl 1):s110–s124. https://doi.org/10.1111/hdi.12567
Haidar MA, Loya F, Yang Y, Lin H, Glassman A, Keating MJ, Goldwasser E, Albitar M (1996) Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence. Nucl Acids Res 24:3621–3628
Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277:26351–26355
Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, Bradfield CA (1997) Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272:8581–8593
Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY (2002) Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417:975–978. https://doi.org/10.1038/nature00767
Honda H, Hosaka N, Ganz T, Shibata T (2019) Iron metabolism in chronic kidney disease patients. Contrib Nephrol 198:103–111. https://doi.org/10.1159/000496369
Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in stem cells. Mol Cell Biol 26:3514–3526
Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987–7992
Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822–826
Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595–10599
Ivan M, Haberberger T, Gervasi DC, Michelson KS, Günzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, Kaelin WG Jr (2002) Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99:13459–13464
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468
Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12:149–162
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472
Kaelin WG Jr (2010) New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann NY Acad Sci 1210:1–7. https://doi.org/10.1111/j.1749-6632.2010.05781.x
Kallio PJ, Wilson WJ, O’Brien S, Makino Y, Poellinger L (1999) Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 274:6519–6525
Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97:10430–10435
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012) Kidney Int Suppl 2:279–335
Keith B, Johnson RS, Simon MC (2011) HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9–22
Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444–1446
Köditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, Myllyharju J, Wenger RH, Katschinski DM (2007) Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110:3610–3617
Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG Jr (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484–488
Kolk-Vegter AJ, Bosch E, van Leeuwen AM (1971) Influence of serum hepatitis on haemoglobin level in patients on regular haemodialysis. Lancet 1:526–528. https://doi.org/10.1016/s0140-6736(71)91127-5
Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr (2003) Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83. https://doi.org/10.1371/journal.pbio.0000083
Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237–246
Koong AC, Chen EY, Mivechi NF, Denko NC, Stambrook P, Giaccia AJ (1994) Hypoxic activation of nuclear factor-κ B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res 54:5273–5279
Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ (2010) Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 α enhances hypoxic gene expression and tumor growth. Mol Cell Biol 30:344–353. https://doi.org/10.1128/mcb.00444-09
Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435–5443
Kvietikova I, Wenger RH, Marti HH, Gassmann M (1995) The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucl Acids Res 23:4542–4550
Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466–1471
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320. https://doi.org/10.1126/science.8493574
Levy AP, Levy NS, Goldberg MA (1996) Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271:25492–25497
Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746–2753
Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG Jr, Goldberg MA (1997) Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 51:575–578
Liu Q, Davidoff O, Niss K, Haase VH (2012) Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 122:4635–4644. https://doi.org/10.1172/jci63924
Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732–741
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339:1621–1625. https://doi.org/10.1126/science.1231677
Madan A, Lin C, Hatch SLI, Curtin PT (1995) Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85:2735–2741
Madsen CD, Pedersen JT, Venning FA, Singh LB, Moeendarbary E, Charras G, Cox TR, Sahai E, Erler JT (2015) Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep 16:1394–1408. https://doi.org/10.15252/embr.201540107
Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675–2686
Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C (2009) HIF-2α, but not HIF-1α, promotes iron absorption in mice. J Clin Invest 119:1159–1166
Maxwell PH, Eckardt KU (2016) HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 12:157–168. https://doi.org/10.1038/nrneph.2015.193
Maxwell PH, Ferguson DJ, Osmond MK, Pugh CW, Heryet A, Doe BG, Johnson MH, Ratcliffe PJ (1994) Expression of a homologously recombined erythopoietin-SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 84:1823–1830
Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ (1993) Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44:1149–1162
Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ (1994) Erythropoietin-producing cells in transgenic mice expressing SV40 large T antigen directed by erythropoietin control sequences. Ann NY Acad Sci 718:356–358
Maxwell PH, Pugh CW, Ratcliffe PJ (1993) Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 90:2423–2427
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275
McDonough MA, Loenarz C, Chowdhury R, Clifton IJ, Schofield CJ (2010) Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 20:659–672. https://doi.org/10.1016/j.sbi.2010.08.006
Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Burgel T, Jelkmann W, Acker H, Fandrey J (2003) Intracellular localisation of human HIF-1 α hydroxylases: implications for oxygen sensing. J Cell Sci 116:1319–1326. https://doi.org/10.1242/jcs.00318
Mimura I, Nangaku M, Kanki Y, Tsutsumi S, Inoue T, Kohro T, Yamamoto S, Fujita T, Shimamura T, Suehiro J, Taguchi A, Kobayashi M, Tanimura K, Inagaki T, Tanaka T, Hamakubo T, Sakai J, Aburatani H, Kodama T, Wada Y (2012) Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol 32:3018–3032
Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP (2002) Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296:1886–1889
Minamishima YA, Kaelin WG Jr (2010) Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329:407. https://doi.org/10.1126/science.1192811
Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr (2008) Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111:3236–3244
Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr (2009) A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol 29:5729–5741
Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284:16767–16775
Myllyharju J, Koivunen P (2013) Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles. Biol Chem 394:435–448. https://doi.org/10.1515/hsz-2012-0328
Nolan KA, Wenger RH (2018) Source and microenvironmental regulation of erythropoietin in the kidney. Curr Opin Nephrol Hypertens 27:277–282. https://doi.org/10.1097/mnh.0000000000000420
Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM (2001) Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104:2216–2221. https://doi.org/10.1161/hc4301.097193
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423–427
Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L (2010) Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucl Acids Res 38:2332–2345
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032. https://doi.org/10.1056/NEJMoa0907845
Platt JL, Salama R, Smythies J, Choudhry H, Davies JO, Hughes JR, Ratcliffe PJ, Mole DR (2016) Capture-C reveals preformed chromatin interactions between HIF-binding sites and distant promoters. EMBO Rep 17:1410–1421. https://doi.org/10.15252/embr.201642198
Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB (2016) Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clinical journal of the American Society of Nephrology : CJASN 11:982–991. https://doi.org/10.2215/cjn.06890615
Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ (1997) Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J Biol Chem 272:11205–11214
Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E et al (2011) Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43:60–65. https://doi.org/10.1038/ng.723
Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, Haase VH (2007) Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117:1068–1077
Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675–5686
Reischl S, Li L, Walkinshaw G, Flippin LA, Marti HH, Kunze R (2014) Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLoS One 9:e84767
Rossert J, Casadevall N, Eckardt KU (2004) Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15:398–406. https://doi.org/10.1097/01.asn.0000107561.59698.42
Ryan HE, Lo J, Johnson RS (1998) HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005–3015
Salama R, Masson N, Simpson P, Sciesielski LK, Sun M, Tian YM, Ratcliffe PJ, Mole DR (2015) Heterogeneous effects of direct hypoxia pathway activation in kidney cancer. PLoS One 10:e0134645. https://doi.org/10.1371/journal.pone.0134645
Salceda S, Caro J (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642–22647
Sanghani NS, Haase VH (2019) Hypoxia-inducible factor activators in renal anemia: current clinical experience. Ad Chronic Kidney Dis 26:253–266. https://doi.org/10.1053/j.ackd.2019.04.004
Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271–276. https://doi.org/10.1038/nchembio.1185
Schley G, Klanke B, Kalucka J, Schatz V, Daniel C, Mayer M, Goppelt-Struebe M, Herrmann M, Thorsteinsdottir M, Palsson R, Beneke A, Katschinski DM, Burzlaff N, Eckardt KU, Weidemann A, Jantsch J, Willam C (2019) Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis. Kidney Int 96:378–396. https://doi.org/10.1016/j.kint.2019.02.016
Schödel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, Tomlinson IP, Ratcliffe PJ, Mole DR (2012) Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet 44(420-425):S421–S422
Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR (2011) High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117:e207–e217
Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY (2017) Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia 5:1–9. https://doi.org/10.2147/hp.s130526
Semenza GL (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167–171
Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148:399–408. https://doi.org/10.1016/j.cell.2012.01.021
Semenza GL, Dureza RC, Traystman MD, Gearhart JD, Antonarakis SE (1990) Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Mol Cell Biol 10:930–938
Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE (1991) Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci USA 88:8725–8729
Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE (1991) Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 88:5680–5684
Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763
Semenza GL, Traystman MD, Gearhart JD, Antonarakis SE (1989) Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci USA 86:2301–2305
Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454
Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ (2009) Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 9:152–164
Shalhoub RJ, Rajan U, Kim VV, Goldwasser E, Kark JA, Antoniou LD (1982) Erythrocytosis in patients on long-term hemodialysis. Ann Intern Med 97:686–690. https://doi.org/10.7326/0003-4819-97-5-686
Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG Jr (2011) Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 1:222–235
Simonson TS, McClain DA, Jorde LB, Prchal JT (2012) Genetic determinants of Tibetan high-altitude adaptation. Hum Genet 131:527–533. https://doi.org/10.1007/s00439-011-1109-3
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098. https://doi.org/10.1056/NEJMoa065485
Srinivas V, Zhang LP, Zhu XH, Caro J (1999) Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem Biophys Res Commun 260:557–561
Strowitzki MJ, Cummins EP, Taylor CT (2019) Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous? Cells 8. https://doi.org/10.3390/cells8050384
Sugahara M, Tanaka T, Nangaku M (2017) Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int 92:306–312. https://doi.org/10.1016/j.kint.2017.02.035
Sutter CH, Laughner E, Semenza GL (2000) Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 97:4748–4753
Suzuki N, Obara N, Pan X, Watanabe M, Jishage K, Minegishi N, Yamamoto M (2011) Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol 31:3896–3905
Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK (2008) Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 74:791–798. https://doi.org/10.1038/ki.2008.295
Takahashi Y, Takahashi S, Shiga Y, Yoshimi T, Miura T (2000) Hypoxic induction of prolyl 4-hydroxylase α (I) in cultured cells. J Biol Chem 275:14139–14146
Tambuwala MM, Manresa MC, Cummins EP, Aversa V, Coulter IS, Taylor CT (2015) Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis. J Control Release 217:221–227. https://doi.org/10.1016/j.jconrel.2015.09.022
Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1α by the von hippel-lindau tumor suppressor protein. EMBO J 19:4298–4309
Tanimoto K, Tsuchihara K, Kanai A, Arauchi T, Esumi H, Suzuki Y, Sugano S (2011) Genome-wide identification and annotation of HIF-1α binding sites in two cell lines using massively parallel sequencing. Hugo J 4:35–48
Tausendschön M, Rehli M, Dehne N, Schmidl C, Doring C, Hansmann ML, Brüne B (2015) Genome-wide identification of hypoxia-inducible factor-1 and -2 binding sites in hypoxic human macrophages alternatively activated by IL-10. Biochim Biophys Acta 1849:10–22. https://doi.org/10.1016/j.bbagrm.2014.10.006
Taylor CT, Colgan SP (2017) Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol 17:774–785. https://doi.org/10.1038/nri.2017.103
Taylor MS (2001) Characterization and comparative analysis of the EGLN gene family. Gene 275:125–132. https://doi.org/10.1016/s0378-1119(01)00633-3
Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72–82
Tiana M, Acosta-Iborra B, Puente-Santamaria L, Hernansanz-Agustin P, Worsley-Hunt R, Masson N, Garcia-Rio F, Mole D, Ratcliffe P, Wasserman WW, Jimenez B, Del Peso L (2018) The SIN3A histone deacetylase complex is required for a complete transcriptional response to hypoxia. Nucl Acids Res 46:120–133. https://doi.org/10.1093/nar/gkx951
Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massague J (2013) Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 19:50–56. https://doi.org/10.1038/nm.3029
Vogler M, Zieseniss A, Hesse AR, Levent E, Tiburcy M, Heinze E, Burzlaff N, Schley G, Eckardt KU, Willam C, Katschinski DM (2015) Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Eur J Physiol 467:2141–2149. https://doi.org/10.1007/s00424-014-1667-z
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514
Wang GL, Semenza GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304–4308
Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237
Warnecke C, Weidemann A, Volke M, Schietke R, Wu X, Knaup KX, Hackenbeck T, Bernhardt W, Willam C, Eckardt KU, Wiesener MS (2008) The specific contribution of hypoxia-inducible factor-2α to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res 314:2016–2027. https://doi.org/10.1016/j.yexcr.2008.03.003
Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J 18:1462–1464
Wenger RH (2000) Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203:1253–1263
Wenger RH, Kurtz A (2011) Erythropoietin. Compr Physiol 1:1759–1794
Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005:re12
Whyte MK, Walmsley SR (2014) The regulation of pulmonary inflammation by the hypoxia-inducible factor-hydroxylase oxygen-sensing pathway. Ann Am Thorac Soc 11(Suppl 5):s271–s276. https://doi.org/10.1513/AnnalsATS.201403-108AW
Winning S, Splettstoesser F, Fandrey J, Frede S (2010) Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: the role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-κ B. J Immunol 185:1786–1793. https://doi.org/10.4049/jimmunol.0903244
Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Nunez J, Perahia AJ, Wood JC (2018) Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol 47:72–83. https://doi.org/10.1159/000486968
Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, Kung AL (2009) Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106:4260–4265. https://doi.org/10.1073/pnas.0810067106
Yamashita T, Ohneda O, Nagano M, Iemitsu M, Makino Y, Tanaka H, Miyauchi T, Goto K, Ohneda K, Fujii-Kuriyama Y, Poellinger L, Yamamoto M (2008) Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS. Mol Cell Biol 28:1285–1297. https://doi.org/10.1128/mcb.01332-07
Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T et al (2017) VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov 7:1284–1305. https://doi.org/10.1158/2159-8290.cd-17-0375
Funding
RHW was supported by the National Centre of Competence in Research “Kidney.CH” and the Swiss National Science Foundation (310030_184813); and JS received funding from the German Research Foundation (387509280-SFB 1350 C5).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fandrey, J., Schödel, J., Eckardt, KU. et al. Now a Nobel gas: oxygen. Pflugers Arch - Eur J Physiol 471, 1343–1358 (2019). https://doi.org/10.1007/s00424-019-02334-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00424-019-02334-8